updat‎e on the Treatment of Metastatic Urothelial Carcinoma

Platinum-based combination chemotherapy has been the standard of care in the frst-line treatment of metastatic urothelial carcinoma (mUC). Treatment of metastatic disease following progression on platinum-based regimens has evolved signifcantly in the last few years. Clinical trials are currently ongoing to determine how best to use and sequence these treatments. In this minireview, we will review current frst-line treatment options in both cisplatin ft and cisplatin unft patients and advances in frstand second-line treatments including chemotherapy and immunotherapy. Tis review reports key fndings from the clinical trials especially highlighting the importance of PD-1 and PD-L1 inhibitors in the treatment of bladder/urothelial carcinomas.